Kiniksa Pharmaceuticals
KNSA
154 hedge funds and large institutions have $768M invested in Kiniksa Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 51 increasing their positions, 49 reducing their positions, and 20 closing their positions.
65% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 20
42% more call options, than puts
Call options by funds: $4.38M | Put options by funds: $3.09M
28% more capital invested
Capital invested by funds: $600M → $768M (+$168M)
8% more funds holding
Funds holding: 142 → 154 (+12)
4% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 49
0.74% more ownership
Funds ownership: 96.67% → 97.41% (+0.74%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$61.2M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$27.2M |
| 3 |
BlackRock
New York
|
+$19.8M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$8.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$13.9M |
| 2 |
Morgan Stanley
New York
|
-$6.34M |
| 3 |
GC
GMT Capital
Atlanta,
Georgia
|
-$5.99M |
| 4 |
Walleye Capital
New York
|
-$5.74M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$3.99M |
KNSA Hedge Fund Activity: Q1 2024 in Review
154 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q1 2024, worth a combined $768M — up 28% from $600M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new KNSA positions and 20 closed out — a net gain of 13 holders — while 51 added to existing stakes and 49 trimmed.
The largest buyer was HHLR Advisors, opening a new position worth an estimated $61.2M. The largest seller was Rubric Capital Management (New York), cutting an estimated $13.9M.
- 154 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q1 2024, up from 142 in Q4 2023.
- Funds reported $768M of Kiniksa Pharmaceuticals stock for Q1 2024, up 28% quarter-over-quarter.
- 33 funds opened new Kiniksa Pharmaceuticals positions in Q1 2024 and 20 closed out, a net change of +13 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q1 2024 was HHLR Advisors, an estimated $61.2M added.
- The largest Kiniksa Pharmaceuticals seller in Q1 2024 was Rubric Capital Management (New York), an estimated $13.9M sold.
Based on aggregated 13F filings for Q1 2024.